LifeSci Acquisition II in its latest filing included a balance sheet showing $80 million in net proceeds from the SPAC’s IPO and private placement.
The SPAC said it is targeting companies in North America or Europe that are developing assets in the biopharma, medical technology, digital health, and healthcare services sectors. Read more.
